HK15497A - Crystalline beta-lactam hydrate - Google Patents

Crystalline beta-lactam hydrate Download PDF

Info

Publication number
HK15497A
HK15497A HK15497A HK15497A HK15497A HK 15497 A HK15497 A HK 15497A HK 15497 A HK15497 A HK 15497A HK 15497 A HK15497 A HK 15497A HK 15497 A HK15497 A HK 15497A
Authority
HK
Hong Kong
Prior art keywords
solution
stirred
minutes
water
suspension
Prior art date
Application number
HK15497A
Other languages
German (de)
English (en)
Inventor
Elaine Pasini Carol
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HK15497A publication Critical patent/HK15497A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D463/00—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D463/10—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D463/14—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hetero atoms directly attached in position 7
    • C07D463/16—Nitrogen atoms
    • C07D463/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D463/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D463/22—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (5)

  1. Procédé pour préparer la forme monohydratée cristalline du composé de formule (I) qui comprend le réglage du pH d'une solution aqueuse contenant un composé de formule (I) à une valeur d'environ 2 à 6.
  2. Procédé selon la revendication 1, dans lequel le pH est réglé à une valeur d'environ 4 à 5.
  3. Procédé pour préparer une formulation pharmaceutique, comprenant le mélange d'un monohydrate cristallin du composé de formule (I), que l'on obtient par un procédé selon la revendication 1, avec un ou plusieurs supports, véhicules ou excipients pharmaceutiquement acceptables pour le composé.
HK15497A 1987-10-06 1997-02-05 Crystalline beta-lactam hydrate HK15497A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10576687A 1987-10-06 1987-10-06

Publications (1)

Publication Number Publication Date
HK15497A true HK15497A (en) 1997-02-14

Family

ID=22307671

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15497A HK15497A (en) 1987-10-06 1997-02-05 Crystalline beta-lactam hydrate

Country Status (32)

Country Link
EP (1) EP0311366B1 (fr)
JP (1) JP2641745B2 (fr)
KR (1) KR970002637B1 (fr)
CN (1) CN1029966C (fr)
AR (1) AR248407A1 (fr)
AT (1) ATE103916T1 (fr)
AU (1) AU598155B2 (fr)
BG (1) BG47036A3 (fr)
CA (1) CA1334970C (fr)
CS (1) CS270594B2 (fr)
DD (1) DD273634A5 (fr)
DE (1) DE3888913T2 (fr)
DK (1) DK170070B1 (fr)
EG (1) EG18529A (fr)
ES (1) ES2063049T3 (fr)
FI (1) FI884554L (fr)
HK (1) HK15497A (fr)
HU (1) HU206348B (fr)
IE (1) IE62108B1 (fr)
IL (1) IL87905A (fr)
MX (1) MX13277A (fr)
MY (1) MY104063A (fr)
NO (1) NO884416L (fr)
NZ (1) NZ226450A (fr)
OA (1) OA08958A (fr)
PH (1) PH31002A (fr)
PL (1) PL152022B1 (fr)
PT (1) PT88662B (fr)
SU (1) SU1731058A3 (fr)
UA (1) UA19149A (fr)
YU (1) YU46699B (fr)
ZA (1) ZA887409B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY103554A (en) * 1987-10-07 1993-07-31 Lilly Co Eli Manohydrate and solvates of a new (beta)-lactam antibiotic.
CA2002596A1 (fr) * 1988-11-14 1990-05-14 Thomas M. Eckrich Hydrates de beta-lactam antibiotiques
CA2002597C (fr) * 1988-11-14 1999-03-23 Thomas M. Eckrich Solvates de beta-lactam antibiotiques
CA2034592C (fr) * 1990-01-26 2001-06-05 Ralph R. Pfeiffer Chlorhydrate crystallin d'un nouvel antibiotique de type beta-lactame et procede pour sa fabrication
US5399686A (en) * 1993-06-04 1995-03-21 Eli Lilly And Company Loracarbef isopropanolate and a process for converting loracarbef isopropanolate to loracarbef monohydrate
US5352782A (en) * 1993-06-04 1994-10-04 Eli Lilly And Company Process for preparing crystalline β-lactam monohydrate
US5374719A (en) * 1993-06-04 1994-12-20 Eli Lilly And Company Process for converting loracarbef dihydrate to loracarbef monohydrate
US5550231A (en) * 1993-06-15 1996-08-27 Eli Lilly And Company Loracarbef hydrochloride C1-C3 alcohol solvates and uses thereof
US5412094A (en) * 1993-06-28 1995-05-02 Eli Lilly And Company Bicyclic beta-lactam/paraben complexes
US5580977A (en) * 1995-03-01 1996-12-03 Eli Lilly And Company Process for preparing loracarbef monohydrate
US6001996A (en) * 1995-05-11 1999-12-14 Eli Lilly And Company Complexes of cephalosporins and carbacephalosporins with parabens
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1429756B1 (fr) 2001-09-21 2006-11-22 Schering Corporation Methodes et combinaisons therapeutiques utiles pour le traitement du xanthome effectue avec des inhibiteurs d'absorption du sterol
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2006508188A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 脱髄の処置のためのコレステロール吸収インヒビター
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655656A (en) * 1970-06-04 1972-04-11 Lilly Co Eli Crystalline cephalexin monohydrate
JPS5672698A (en) * 1979-11-14 1981-06-16 Kyowa Hakko Kogyo Co Ltd Preparation of optically active cephalosporin analogue
MY103554A (en) * 1987-10-07 1993-07-31 Lilly Co Eli Manohydrate and solvates of a new (beta)-lactam antibiotic.

Also Published As

Publication number Publication date
BG47036A3 (bg) 1990-04-16
YU184588A (en) 1990-02-28
EP0311366A1 (fr) 1989-04-12
MY104063A (en) 1993-11-30
NO884416D0 (no) 1988-10-05
DK170070B1 (da) 1995-05-15
OA08958A (en) 1990-11-30
AR248407A1 (es) 1995-08-18
KR970002637B1 (ko) 1997-03-07
DE3888913D1 (de) 1994-05-11
DK553788A (da) 1989-04-07
CA1334970C (fr) 1995-03-28
FI884554A7 (fi) 1989-04-07
ES2063049T3 (es) 1995-01-01
ZA887409B (en) 1990-06-27
CN1032793A (zh) 1989-05-10
CS270594B2 (en) 1990-07-12
YU46699B (sh) 1994-04-05
AU2337288A (en) 1989-04-06
PT88662A (pt) 1988-11-01
EP0311366B1 (fr) 1994-04-06
PL275093A1 (en) 1989-05-02
IL87905A (en) 1992-06-21
DK553788D0 (da) 1988-10-04
FI884554L (fi) 1989-04-07
PT88662B (pt) 1992-12-31
IE883015L (en) 1989-04-06
NO884416L (no) 1989-04-07
HU206348B (en) 1992-10-28
HUT48884A (en) 1989-07-28
SU1731058A3 (ru) 1992-04-30
JPH01128983A (ja) 1989-05-22
MX13277A (es) 1993-11-01
KR890006644A (ko) 1989-06-15
CS666688A2 (en) 1989-11-14
UA19149A (uk) 1997-12-25
ATE103916T1 (de) 1994-04-15
DD273634A5 (de) 1989-11-22
DE3888913T2 (de) 1994-08-11
JP2641745B2 (ja) 1997-08-20
EG18529A (en) 1993-04-30
IL87905A0 (en) 1989-03-31
IE62108B1 (en) 1994-12-14
CN1029966C (zh) 1995-10-11
PL152022B1 (en) 1990-10-31
NZ226450A (en) 1990-05-28
PH31002A (en) 1997-12-23
FI884554A0 (fi) 1988-10-04
AU598155B2 (en) 1990-06-14

Similar Documents

Publication Publication Date Title
EP0311366B1 (fr) Hydrate cristallin de bêta-lactame
AU620659B2 (en) Hydrate forms of 1-carbacephalosporin derivatives
US5407929A (en) Triazolylthiomethylthio cephalosporin hydrochhloride, its crystalline hydrate and the production of the same
RU2125571C1 (ru) СОЛЬ 7-([1α,5α,6α]-6-АМИНО-3-АЗАБИЦИКЛО [3.1.0] ГЕКС-3-ИЛ)-6-ФТОР-1-(2,4-ДИФТОРФЕНИЛ)-1,4- ДИГИДРО-4-ОКСО-1,8-НАФТИРИДИН-3-КАРБОНОВОЙ И МЕТАНСУЛЬФОНОВОЙ КИСЛОТ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
AU615026B2 (en) Crystalline beta-lactam solvate
EP0439353B1 (fr) Hydrochlorure cristallin d'un nouvel antibiotique bêta-lactame et procédé de préparation
US4863915A (en) β-lactam antibiotics
AU605635B2 (en) Monohydrate and solvates of a new beta-lactam antibiotic
CA2494288A1 (fr) Nouveau sel et polymorphes d'hemifumarate dedesloratadine
KR100274736B1 (ko) 6-엔-(엘-에이엘에이-엘-에이엘에이)-트로바플록사신 전구약물의 폴리모프
JPS62142185A (ja) セフロキシムのエステル類

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20081004